Mission EB
In the first large-scale stem cell clinical trial in epidermolysis bullosa (EB), the “MissionEB” study, CORDStrom was investigated in a double-blinded, randomized, placebo-controlled pivotal trial to evaluate the safety and efficacy of CORDStrom in 30 pediatric patients in the UK with intermediate and severe RDEB using a novel crossover clinical trial design. Topline results showed CORDStrom was easily administered, well tolerated, with no serious adverse effects related to treatment, and there were beneficial effects with respect to itch, pain, disease severity and quality of life measures.
MINDFuL
Phase 2 trial of XPro for early and mild Alzheimer’s disease
The MINDFuL study investigates XProTM in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.
The MINDFuL study will compare XProTM to placebo (an injection that looks like the investigational drug but does not contain active medicine) to find out whether XProTM affects memory, functioning, and behavior. The study will also evaluate whether XProTM is safe and tolerable.
This study runs for 6 months in which some participants receive the study drug and some receive the placebo. During this time, measurements will be made by brain imaging (MRI), by blood collection, and cognitive testing.
CaRe Prostate
Study of INKmune in Patients with metastatic castrate-resistant prostate cancer
CaRe Prostate is a Phase I/II, open label, dose escalation and expansion study of INKmune therapy in patients with metastatic castration resistant prostate cancer (mCRPC). The study is being conducted in the US.
footer contact
Interested to learn more? Please contact us at [email protected]
Contact Us
footer signup
Subscribe to receive the latest updates
Sign Up